[Funding alert] Cytonus Therapeutics Raises $11.7 Mn in Series A Round

Read also - [Funding alert] AssemblyAI Raises $50M in Series C Funding Round led by Accel

The unconventional approach flips the script on cell therapy. Rather than using the cell as a medicine itself, a partially-gutted cell transports a drug to a specified address in the body, thanks to molecular homing beacons appended to its surface.

Read also - [Funding alert] TX-based Medical Device Company EndoQuest Robotics Secures $42M in C-1 Funding

“In many ways, it behaves like a biological drone. It’s an entirely new category of drug delivery,” Cytonus co-founder and CEO Remo Moomiaie-Qajar said in an exclusive interview. “We are not a cell therapy company.”

Read also - [Funding alert] Polaris Electro-Optics Raises $3 Mn Seed Round to Revolutionize Optical Interconnects

“Other approaches like nanoparticles, exosomes, even red blood cells, are all passive ways to deliver a product. They circulate in the bloodstream and are very inefficient at getting out and penetrating deep into tissues,” Moomiaie-Qajar said. “The Cargocyte is different. It’s an active transporter, better at homing and migration than anything else.”

Read also - [Funding alert] NYC-based Syrup Secures $17.5M in Funding

About Cytonus Therapeutics

Cytonus Therapeutics is a San Diego-based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases, and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas.

Read also - [Funding alert] NYC-based Trackstar Secures $2.6M in Seed Funding